EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
104 hedge funds and large institutions have $54M invested in Eagle Pharmaceuticals, Inc. in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 42 increasing their positions, 25 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
104
Holders Change
-3
Holders Change %
-2.8%
% of All Funds
1.52%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
23
Increased
42
Reduced
25
Closed
26
Calls
$522K
Puts
$58K
Net Calls
+$464K
Net Calls Change
+$463K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$2.25M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$1.29M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.1M |
| 4 |
Two Sigma Advisers
New York
|
+$1.04M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$953K |
